Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3739 - Phase I/II trial of weekly nab-Paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer

Presenters

Takashi Ninomiya

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

T. Ninomiya1, K. Hotta2, K. Ohashi1, T. Kubo1, D. Harada3, T. Kozuki3, N. Nogami3, I. Oze4, S. Hosokawa5, A. Bessho5, H. Yoshioka6, K. Kudo7, S. Kuyama7, S. Harita8, I. Takata9, N. Fujimoto10, T. Moritaka11, H. Ichikawa12, N. Takigawa13, K. Kiura1

Author affiliations

  • 1 Respiratory Medicine, Okayama University Hospital, 700-8558 - Okayama/JP
  • 2 Center For Innovative Clinical Medicine, Okayama University Hospital, 7008558 - Okayama/JP
  • 3 Respiratory Medicine, National Hospital Organization Shikoku Cancer Center, 7920280 - Matsuyama/JP
  • 4 Division Of Molecular And Clinical Epidemiology, Aichi Cancer Center, 4648681 - Nagoya/JP
  • 5 Department Of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 700-8607 - Okayama/JP
  • 6 Department Of Respiratory Medicine, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 7 Respiratory Medicine, Iwakuni Medical Center, 7400037 - Iwakuni/JP
  • 8 Respiratory Medicine, Chugoku Central Hospital, 7200001 - Fukuyama/JP
  • 9 Respiratory Medicine, Fukuyama City Hospital, 7218511 - Fukuyama/JP
  • 10 Department Of Medical Oncology, Okayama Rosai Hospital, 7028055 - Okayama/JP
  • 11 Respiratory Medicine, Ehime Prefectural Central Hospital, 7900024 - Matsuyama/JP
  • 12 Respiratory Medicine, KKR Takamatsu Hospital, 7600018 - Takamatsu/JP
  • 13 Internal Medicine 4, Kawasaki Medical School General Medical Center, 7000821 - Okayama/JP
More

Resources

Abstract 3739

Background

Although nab-PTX plus carboplatin is one of the standard treatment for chemo-naive advanced non-small cell lung cancer (NSCLC), the efficacy, safety and optimal schedule of nab-PTX monotherapy as 2nd or 3rd line for NSCLC pts without any driver mutations remains unknown.

Methods

This was a single arm phase I/II study. Eligible pts are advanced NSCLC without EGFR mutation and ALK rearrangement that progressed after platinum-doublet chemotherapy. The pts were received 100 mg/m2 of nab-PTX on day 1, 8, 15 and 22 (level 0) or on day 1, 8, and 15 (level -1) every 4-week in phase I. Dose limiting toxicities (DLT) were assessed and the recommended schedule was determined in the phase I. The primary endpoint was objective response rate (ORR), assuming that estimated ORR was 15% and threshold ORR was 5% with α error of 0.05 and β error of 0.2 in the phase II part. Total 55 pts were planned to be enrolled.

Results

The recommended schedule of nab-PTX was determined as the level -1, because the DLTs were found in 4 of 5 pts in level 0. Total 55 pts were enrolled in the phase II and the characteristics were as followings; median age, 66 years (range, 41–90 years), male/female = 40/15, PS 0/1/2 = 12/39/4, 2nd/3rd line = 34/21, adeno/squamous/large/others = 34/17/2/2. The median number of treatment cycles was three (range, 1–10). The ORR was 7.3% (95% [CI], 2.0 – 17.6%) (PR (n = 4), SD (n = 26), PD (n = 24), and NE (n = 1)). At the median follow-up time of 5.3 months (range, 1.9 – 26.0 months) for all pts, the median PFS was 3.4 months (95%[CI], 1.9 – 4.0 months). Treatment related grade 3 or 4 toxicities were neutropenia (36%), pulmonary infection (3.6%), and pneumonitis (5.4%). One patient (2%) was died due to treatment-related ARDS.

Conclusions

In phase I part, we confirmed that schedule level -1 was tolerable and the schedule had been recommended. In phase II part, this study failed to meet predefined primary endpoint although PFS was comparable and toxicity was acceptable for pts with advanced NSCLC without any driver mutations as 2nd or 3rd line treatment.

Clinical trial identification

UMIN000012404.

Legal entity responsible for the study

Okayama Lung Cancer Study Group

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.